OBJECTIVES: To analyze virological and immunological features of AIDS-related progressive multifocal leukoencepalophathy (PML) and their association to disease prognosis. METHODS: In HIV-infected patients with virologically confirmed PML, JC virus (JCV) DNA load and levels of Macrophage Chemoattractant Protein (MCP)-1 were determined in cerebrospinal fluid. JCV genotypes, rearrangements and JCV DNA binding sites for cellular transcription factors were analyzed by sequencing the viral VP1 region and regulatory region (RR). RESULTS: 45 patients were analyzed: 60% were exposed to highly active antiretroviral therapy (HAART) after PML and 24% before the disease onset. JCV DNA load in cerebrospinal fluid was a strong predictor of patients survival. Lower levels of JCV DNA in cerebrospinal fluid were associated with the following virologic factors: viral genotype 4 (p = 0.043), more rearrangements in the RR (p = 0.046), duplication of RR block B (p = 0.028), and duplication of binding sites for cellular transcription factor NF-1 (p = 0.060). In patients with prior antiretroviral exposure there was a trend towards a higher number of binding sites for cellular transcription factors (p = 0.068). Lower JCV load was also predicted by exposure to HAART (p = 0.010), higher baseline CD4 counts (p = 0.009) and higher cerebrospinal fluid MCP-1 levels (p = 0.036). In a multiple regression model, MCP-1 levels were independently associated with JCV load. CONCLUSION: HAART leads to a partial immune-mediated control of JCV replication; the virus may tend to escape through the selection of rearrangements in the RR, some associated with enhanced viral replication efficiency, other resulting in multiplication of binding sites for cellular transcription factors.
OBJECTIVES: To analyze virological and immunological features of AIDS-related progressive multifocal leukoencepalophathy (PML) and their association to disease prognosis. METHODS: In HIV-infectedpatients with virologically confirmed PML, JC virus (JCV) DNA load and levels of Macrophage Chemoattractant Protein (MCP)-1 were determined in cerebrospinal fluid. JCV genotypes, rearrangements and JCV DNA binding sites for cellular transcription factors were analyzed by sequencing the viral VP1 region and regulatory region (RR). RESULTS: 45 patients were analyzed: 60% were exposed to highly active antiretroviral therapy (HAART) after PML and 24% before the disease onset. JCV DNA load in cerebrospinal fluid was a strong predictor of patients survival. Lower levels of JCV DNA in cerebrospinal fluid were associated with the following virologic factors: viral genotype 4 (p = 0.043), more rearrangements in the RR (p = 0.046), duplication of RR block B (p = 0.028), and duplication of binding sites for cellular transcription factor NF-1 (p = 0.060). In patients with prior antiretroviral exposure there was a trend towards a higher number of binding sites for cellular transcription factors (p = 0.068). Lower JCV load was also predicted by exposure to HAART (p = 0.010), higher baseline CD4 counts (p = 0.009) and higher cerebrospinal fluid MCP-1 levels (p = 0.036). In a multiple regression model, MCP-1 levels were independently associated with JCV load. CONCLUSION: HAART leads to a partial immune-mediated control of JCV replication; the virus may tend to escape through the selection of rearrangements in the RR, some associated with enhanced viral replication efficiency, other resulting in multiplication of binding sites for cellular transcription factors.
Authors: Hansjürgen T Agostini; Alison Deckhut; David V Jobes; Rosina Girones; Günther Schlunck; Marcin G Prost; Carolina Frias; E Pérez-Trallero; Caroline F Ryschkewitsch; Gerald L Stoner Journal: J Gen Virol Date: 2001-05 Impact factor: 3.891
Authors: J Gasnault; Y Taoufik; C Goujard; P Kousignian; K Abbed; F Boue; E Dussaix; J F Delfraissy Journal: J Neurovirol Date: 1999-08 Impact factor: 2.643
Authors: Juan Berenguer; Pilar Miralles; Julio Arrizabalaga; Esteban Ribera; Fernando Dronda; Josu Baraia-Etxaburu; Pere Domingo; Manuel Márquez; Francisco J Rodriguez-Arrondo; Fernando Laguna; Rafael Rubio; José Lacruz Rodrigo; J Mallolas; Verónica de Miguel Journal: Clin Infect Dis Date: 2003-04-02 Impact factor: 9.079
Authors: J Gasnault; P Kousignian; M Kahraman; J Rahoiljaon; S Matheron; J F Delfraissy; Y Taoufik Journal: J Neurovirol Date: 2001-08 Impact factor: 2.643
Authors: Chen S Tan; Laura C Ellis; Christian Wüthrich; Long Ngo; Thomas A Broge; Jenny Saint-Aubyn; Janice S Miller; Igor J Koralnik Journal: J Virol Date: 2010-07-07 Impact factor: 5.103
Authors: Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major Journal: Clin Microbiol Rev Date: 2012-07 Impact factor: 26.132
Authors: Clemens Warnke; Til Menge; Hans-Peter Hartung; Michael K Racke; Petra D Cravens; Jeffrey L Bennett; Elliot M Frohman; Benjamin M Greenberg; Scott S Zamvil; Ralf Gold; Bernhard Hemmer; Bernd C Kieseier; Olaf Stüve Journal: Arch Neurol Date: 2010-08
Authors: Valeria Pietropaolo; Anna Bellizzi; Elena Anzivino; Marco Iannetta; Maria Antonella Zingaropoli; Donatella Maria Rodio; Manuela Morreale; Simona Pontecorvo; Ada Francia; Vincenzo Vullo; Anna Teresa Palamara; Maria Rosa Ciardi Journal: J Neurovirol Date: 2015-05-01 Impact factor: 2.643